UNSPSC 51182305: Egrifta or tesamorelin

This classification denotes a growth hormone-releasing hormone analogue with the molecular formula C221H366N72O67S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MQG94M5EEO, chemically known as (3e)-hex-3-enoylsomatoliberin, which bears US NIH Compound Identifier 16137828. European Medicines Agency schedules tesamorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32399. Egrifta or tesamorelin bears US NLM identifiers UMLS ID C1876200 and NCI Concept Code C77425.

UNSPSC 51182305 Egrifta or tesamorelin is a Commodity code covering prescription pharmaceuticals, specifically growth hormone-releasing factor analogs used to treat lipodystrophy and related metabolic conditions. State and local government procurement under this code occurs primarily through cooperative purchasing agreements that bundle individual specialty pharmaceuticals with broader multi-source generic and over-the-counter product contracts. The issuing bodies are state health and social services departments, state prison systems, and participating Medicaid agencies that leverage cooperative purchasing vehicles to achieve volume pricing and streamlined vendor management across multiple jurisdictions. Vendors supplying under this code must maintain current Good Manufacturing Practices certification, comply with the Drug Supply Chain Security Act, hold appropriate pharmaceutical liability insurance, and work through authorized pharmaceutical wholesalers with established chargeback and EDI systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, extending across participating state and local government facilities in Minnesota, Oregon, and other member states. The procurement requires vendors to supply detailed product information including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing locations, with pricing weighted at 75 percent of the evaluation and compliance with administrative data format requirements and EDI capability together representing 15 percent. Awarded contracts are effective July 1, 2026 for an initial two-year term with optional extensions, and vendors must maintain contractual relationships with at least two of three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. All products must be available in the marketplace by May 15, 2026, and MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.